​

Artiva Biotherapeutics (ARTV) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ARTV Stock Forecast

Artiva Biotherapeutics (ARTV) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $4.00 and a low of $4.00. This represents a -1.72% decline from the last price of $4.07.

$3 $4 $5 $6 $7 $8 $9 $10 $11 $12 High: $4 Avg: $4 Low: $4 Last Closed Price: $4.07

ARTV Stock Rating

Artiva Biotherapeutics stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (40.00%), 3 Hold (60.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 3 2 Strong Sell Sell Hold Buy Strong Buy

ARTV Price Target Upside V Benchmarks

TypeNameUpside
StockArtiva Biotherapeutics-1.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts224
Avg Price Target$4.00$4.00$20.75
Last Closing Price$4.07$4.07$4.07
Upside/Downside-1.72%-1.72%409.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26-24--6
Oct, 2615---6
Sep, 2615---6
Aug, 2615---6
Jul, 2615---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2026Jefferies$4.00$4.28-6.54%-1.72%
Oct 27, 2026David NierengartenWedbush$4.00$4.26-6.10%-1.72%
May 11, 2026David NierengartenWedbush$40.00$11.15258.74%882.80%
May 08, 2026H.C. Wainwright$35.00$11.84195.61%759.95%
Aug 13, 2024David NierengartenWedbush$18.00$11.2260.43%342.26%
Aug 13, 2024Gil BlumNeedham$23.00$11.22104.99%465.11%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2026JefferiesBuyHolddowngrade
Oct 27, 2026NeedhamBuyHolddowngrade
Oct 27, 2026WedbushOutperformNeutraldowngrade
Oct 27, 2026Cowen & Co.BuyHolddowngrade
Oct 02, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 02, 2026H.C. WainwrightBuyBuyhold
May 26, 2026Cantor FitzgeraldOverweightOverweighthold
May 12, 2026NeedhamBuyBuyhold
May 11, 2026WedbushOutperformOutperformhold
May 08, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 24 Dec 25
Dec 24Dec 25
Reported$-5.20$-3.43
Avg Forecast$-4.95$-2.83
High Forecast$-3.63$-2.42
Low Forecast$-6.25$-3.21
Surprise %5.05%21.20%

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 24 Dec 25
Dec 24Dec 25
Reported$251.00K-
Avg Forecast$400.00K$75.36M
High Forecast$550.00K$75.36M
Low Forecast$250.00K$75.36M
Surprise %-37.25%-

Net Income Forecast

$-85M $-72M $-59M $-46M $-33M $-20M Dec 24 Dec 25
Dec 24Dec 25
Reported$-58.49M$-83.86M
Avg Forecast$-46.31M$-26.47M
High Forecast$-33.96M$-22.64M
Low Forecast$-58.47M$-30.03M
Surprise %26.32%216.79%

ARTV Forecast FAQ

Is Artiva Biotherapeutics stock a buy?

Artiva Biotherapeutics stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Artiva Biotherapeutics is a neutral investment for most analysts.

What is Artiva Biotherapeutics's price target?

Artiva Biotherapeutics's price target, set by 5 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $4 at the low end to $4 at the high end, suggesting a potential -1.72% change from the previous closing price of $4.07.

How does Artiva Biotherapeutics stock forecast compare to its benchmarks?

Artiva Biotherapeutics's stock forecast shows a -1.72% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Artiva Biotherapeutics over the past three months?

  • November 2026: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.